Hartaj Singh
Stock Analyst at Oppenheimer
(1.78)
# 3,351
Out of 5,116 analysts
106
Total ratings
47.52%
Success rate
-5.92%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $20.34 | +81.91% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $741.45 | +21.38% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $141.95 | -11.94% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $469.90 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $77.55 | - | 6 | Dec 11, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $469.49 | +27.80% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $44.07 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $3.79 | +163.85% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.12 | +5,257.14% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.80 | +400.00% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.63 | +2,353.99% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $11.44 | +92.31% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $15.05 | - | 4 | Jul 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $3.77 | +17,141.38% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $14.48 | +107.18% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $20.34
Upside: +81.91%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $741.45
Upside: +21.38%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $141.95
Upside: -11.94%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $469.90
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $77.55
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $469.49
Upside: +27.80%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $44.07
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $3.79
Upside: +163.85%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.12
Upside: +5,257.14%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.80
Upside: +400.00%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.63
Upside: +2,353.99%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $11.44
Upside: +92.31%
Jul 5, 2023
Downgrades: Perform
Price Target: n/a
Current: $15.05
Upside: -
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $3.77
Upside: +17,141.38%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $14.48
Upside: +107.18%